Equifax (EFX) is back in focus after third quarter numbers and new guidance arrived together, giving investors fresh data on revenue, profit and how management sees the rest of 2026.
Recent headlines have been busy for Equifax, from expanded open banking tools with Mastercard Open Finance on October 16 to the October 20 earnings release and trimmed full year revenue outlook that highlighted ongoing U.S. mortgage market pressure.
That mix of new products, guidance and regulatory questions around mortgage credit reporting has fed into the share price story. A 1 month share price return of 20.75% contrasts with a year to date share price decline of 17.75% and a 1 year total shareholder return that is down 17.00%, while the 3 year total shareholder return of 7.59% points to a more muted longer term payoff so far.
Scan beyond Equifax and see how other data and credit-focused companies are reacting to the same mortgage and regulation story by reviewing our curated 30 resilient stocks with low risk scores .
For Equifax, a 20.75% jump in a month against a weaker year to date track record raises a simple issue: Is this earnings backed repricing, or just sentiment snapping back before the valuation work starts?
Most Popular Narrative: 10% Undervalued
On the most followed view of Equifax, the fair value of about $195.10 sits above the last close at $176.03. This puts the recent bounce in context as a move that still leaves a valuation gap on that framework.
Rapidly growing Work Number records, now at 217 million active records with 108 million unique Social Security numbers, along with high margin Workforce Solutions revenue and 52.1% segment EBITDA margins, are increasing the share of recurring verification income and supporting group level margin expansion.
See why 30 investors see Equifax as 10% undervalued .
Result: Fair Value of $195.10 (UNDERVALUED)
Still, litigation over past credit reporting issues and ongoing mortgage policy debates could pressure Equifax margins and undercut the 10% undervaluation narrative that investors are leaning on.
Find out about the key risks to this Equifax narrative .
Another View: Equifax Through The P/E Lens
That 10% undervalued fair value story looks different once you examine Equifax through its P/E. The stock trades around 27.7x earnings, compared with a 26x fair ratio, a 26.9x peer average and a 22.3x sector level. That gap suggests valuation risk if sentiment cools rather than a clear-cut bargain. So which signal would you trust when the next piece of mortgage or regulatory news lands?
To pressure test that earnings based view against more detailed valuation work, review the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around Equifax valuations and mortgage exposure only matter if you act on them. Weigh both the caution flags and potential upside through the 3 key rewards and 1 important warning sign .
Looking for more investment ideas beyond Equifax?
If Equifax has sharpened your focus on pricing and risk, do not stop here. Broaden your watchlist before the next move leaves you reacting instead of prepared.
-
Target resilient balance sheets by scanning the list of solid balance sheet and fundamentals (24 results) , which can help anchor your portfolio when conditions feel less predictable.
-
Spot potential value opportunities early by reviewing the 29 high quality undervalued stocks , which pair stronger fundamentals with prices that may not fully reflect them.
-
Lock in dependable income streams by assessing the 5 dividend fortresses , which combine higher yields with a focus on stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EFX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
